

Merger investigation into the anticipated acquisition by Cochlear Limited (Cochlear) of the hearing implants division of Demant A/S (Demant)

Case closure summary

On 24 August 2023, the CMA accepted [final undertakings](#) from Cochlear and Demant pursuant to section 82 of the Enterprise Act 2002 (the Final Undertakings). Under the Final Undertakings, Cochlear is prevented from (i) acquiring an interest in Demant's bone conduction solutions (BCS) business or any of its subsidiaries or assets for ten years and (ii) acquiring an interest in Demant's cochlear implants (CI) business or any of its subsidiaries or assets for ten years except pursuant to an agreement approved by the CMA.

On 17 May 2024, the CMA approved the sale of Demant's CI business to Cochlear. This brings the merger investigation to a close.

29 May 2024